- Home
- CVAC vs RCUS Comparison
CVAC vs RCUS Comparison
Compare CVAC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- RCUS
- Stock Information
- Founded
- CVAC 2000
- RCUS 2015
- Country
- CVAC Germany
- RCUS United States
- Employees
- CVAC N/A
- RCUS N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- CVAC Health Care
- RCUS Health Care
- Exchange
- CVAC Nasdaq
- RCUS Nasdaq
- Market Cap
- CVAC 764.4M
- RCUS 906.4M
- IPO Year
- CVAC 2020
- RCUS 2018
- Fundamental
- Price
- CVAC $5.40
- RCUS $8.59
- Analyst Decision
- CVAC Hold
- RCUS Buy
- Analyst Count
- CVAC 3
- RCUS 10
- Target Price
- CVAC $6.83
- RCUS $23.75
- AVG Volume (30 Days)
- CVAC 2.1M
- RCUS 1.1M
- Earning Date
- CVAC 08-14-2025
- RCUS 08-07-2025
- Dividend Yield
- CVAC N/A
- RCUS N/A
- EPS Growth
- CVAC N/A
- RCUS N/A
- EPS
- CVAC 0.87
- RCUS N/A
- Revenue
- CVAC $566,039,775.00
- RCUS $141,000,000.00
- Revenue This Year
- CVAC N/A
- RCUS N/A
- Revenue Next Year
- CVAC $24.04
- RCUS $28.73
- P/E Ratio
- CVAC $6.22
- RCUS N/A
- Revenue Growth
- CVAC 787.60
- RCUS N/A
- 52 Week Low
- CVAC $2.37
- RCUS $6.50
- 52 Week High
- CVAC $5.72
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- CVAC 64.78
- RCUS 47.18
- Support Level
- CVAC $5.33
- RCUS $7.92
- Resistance Level
- CVAC $5.58
- RCUS $8.87
- Average True Range (ATR)
- CVAC 0.12
- RCUS 0.47
- MACD
- CVAC -0.04
- RCUS -0.09
- Stochastic Oscillator
- CVAC 23.81
- RCUS 43.17
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.